Sponsor: Alliance for Clinical Trials in Oncology
Sponsor Study ID: A032201
Study Title: Short Term Intensified Pembrolizumab (Keytruda) And Tivozanib For High-Risk Renal Cell Carcinoma (STRIKE)
CTO #: 104222
NCT Number: NCT06661720
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Kidney
Study Objectives: 2.0 OBJECTIVES 2.1 Primary Objective To compare disease free survival (DFS) as assessed by the investigator for high-risk renal cell carcinoma patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone. 2.2 Secondary Objectives 2.2.1 To compare overall survival (OS) for patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone. 2.2.2 To assess adverse events in each study arm by CTCAE 5.0.